Monday, October 26, 2026
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Dana-Farber/Boston Children’s Tops U.S. Pediatric Cancer Rankings

October 26, 2026
in Cancer
Nathaniel Bowman
By Nathaniel Bowman Scienmag Editorial Profile - Precision Oncology
Reading Time: 2 mins read
0
Dana-Farber/Boston Children’s Tops U.S. Pediatric Cancer Rankings

Dana-Farber/Boston Children’s Tops U.S. Pediatric Cancer Rankings

65
SHARES
587
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the No. 1 pediatric cancer program in the United States in its 2026-2027 Best Children’s Hospitals report. The honor recognizes the Boston-based center’s work across cancer treatment, clinical outcomes, adherence to established care practices and patient-care resources. U.S. News developed the rankings with RTI International by collecting and analyzing data from 114 children’s hospitals and surveying thousands of pediatric specialists. Hospitals selected for a “Best” designation were evaluated on factors including clinical outcomes, compliance with best practices, and the level and quality of resources directly related to patient care.

The distinction follows a sustained record of national recognition: Dana-Farber/Boston Children’s has ranked among the three highest pediatric cancer centers every year since U.S. News began the ranking in 2007, according to the announcement. The center has received more No. 1 rankings than any other program. The result is based on comparative institutional data and specialist assessments rather than a single clinical trial or newly reported treatment outcome. It also does not, by itself, establish that the ranked program produces better survival outcomes than every other pediatric cancer center. Instead, it is a magazine-based assessment of quality measures and resources across a group of hospitals.

Dana-Farber/Boston Children’s brings together Dana-Farber Cancer Institute and Boston Children’s Hospital, two Harvard Medical School affiliates with a shared clinical staff. The partnership provides inpatient care and surgery at Boston Children’s, while most outpatient care is delivered at Dana-Farber Cancer Institute. The two institutions have provided comprehensive care for children with cancer and blood disorders since 1947, combining hospital-based treatment with a research and teaching mission. Their pediatric oncology and hematology teams also train clinicians and investigators, linking patient care to academic medicine and the development of new approaches to childhood cancer.

Leadership at the center attributed the recognition to its emphasis on personalized care, clinical excellence, patient safety and research-led innovation. The ranking covers an organization in which cancer research and clinical care are closely connected; the wider Dana-Farber system says it offers more than 1,200 clinical trials, although the supplied announcement does not specify how many concern pediatric cancer. Separately, U.S. News has ranked Dana-Farber Brigham Cancer Center as the Best Hospital for Cancer in Massachusetts and third nationally, while recognizing Dana-Farber/Boston Children’s as the country’s Best Children’s Hospital for Cancer. Taken together, those designations place Dana-Farber among the few systems recognized in the top three for both adult and pediatric cancer care, according to the release.

Subject of Research: National ranking of the Dana-Farber/Boston Children’s pediatric cancer program based on hospital quality measures and specialist surveys.

Article Title: Dana-Farber/Boston Children's named the top pediatric cancer program in the nation for 2026-2027

Article References: Dana-Farber/Boston Children's named the top pediatric cancer program in the nation for 2026-2027. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: pediatric cancer, Dana-Farber, Boston Children’s, hospital rankings, childhood cancer care, clinical outcomes, patient safety, cancer research, U.S. News, hematology and oncology, Boston, Children's

Cite Scienmag News

Nathaniel Bowman. (October 26, 2026). Dana-Farber/Boston Children’s Tops U.S. Pediatric Cancer Rankings. Scienmag. https://scienmag.com/dana-farber-boston-childrens-tops-u-s-pediatric-cancer-rankings/

Nathaniel Bowman. "Dana-Farber/Boston Children’s Tops U.S. Pediatric Cancer Rankings." Scienmag, 26 October 2026, https://scienmag.com/dana-farber-boston-childrens-tops-u-s-pediatric-cancer-rankings/. Accessed 26 October 2026.

Nathaniel Bowman. "Dana-Farber/Boston Children’s Tops U.S. Pediatric Cancer Rankings." Scienmag. October 26, 2026. https://scienmag.com/dana-farber-boston-childrens-tops-u-s-pediatric-cancer-rankings/

Tags: best practices in pediatric cancer careBostonBoston Children’scancer researchchildhood cancer carechildren'sclinical outcomescomprehensive pediatric blood disorders treatmentDana-FarberDana-Farber/Boston Children’s Hospitalhematology and oncologyhospital rankingshospital resource assessment for pediatric oncologylong-term recognition of pediatric cancer centersnational pediatric cancer center rankingspatient safetypediatric cancerpediatric cancer care quality measurespediatric cancer treatment excellencepediatric cancer treatment rankingspediatric oncology clinical outcomestop U.S. children’s hospitals for cancerU.S. NewsU.S. News & World Report hospital evaluations
Share26Tweet16
Previous Post

Qualitative Study Finds Parent-Reported Sensory Integration Benefits and Access Barriers

Next Post

Ensemble learning improves attack detection across user and network data

Related Posts

Research report: Adjuvant T-DM1 versus trastuzumab plus pertuzumab for residual disease after neoadjuvant dual HER2 blockade in HER2-positive early breast cancer: a multicenter real-world study
Cancer

Research report: Adjuvant T-DM1 versus trastuzumab plus pertuzumab for residual disease after neoadjuvant dual HER2 blockade in HER2-positive early breast cancer: a multicenter real-world study

October 26, 2026
Structured exercise associated with improved survival in cancer meta-analysis
Cancer

Structured exercise associated with improved survival in cancer meta-analysis

October 26, 2026
Bayesian reanalysis supports rituximab–lenalidomide non-inferiority in follicular lymphoma
Cancer

Bayesian reanalysis supports rituximab–lenalidomide non-inferiority in follicular lymphoma

October 26, 2026
Insurance expansion shortened time to BRCA testing and facilitated preventive strategies: a single-center cohort study in Japan
Cancer

Insurance expansion shortened time to BRCA testing and facilitated preventive strategies: a single-center cohort study in Japan

October 26, 2026
AI identifies mesothelioma cells by scattered-light spectra
Cancer

AI identifies mesothelioma cells by scattered-light spectra

October 26, 2026
International observational study tests PANXEON for early pancreatic cancer
Cancer

International observational study tests PANXEON for early pancreatic cancer

October 26, 2026
Next Post
Ensemble learning improves attack detection across user and network data

Ensemble learning improves attack detection across user and network data

  • Mothers who receive childcare support from maternal grandparents show more optimized

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27656 shares
    Share 11059 Tweet 6912
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    1061 shares
    Share 424 Tweet 265
  • Bee body mass, pathogens and local climate influence heat tolerance

    682 shares
    Share 273 Tweet 171
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    546 shares
    Share 218 Tweet 137
  • Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function

    531 shares
    Share 212 Tweet 133
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Ensemble learning improves attack detection across user and network data
  • Dana-Farber/Boston Children’s Tops U.S. Pediatric Cancer Rankings
  • Qualitative Study Finds Parent-Reported Sensory Integration Benefits and Access Barriers
  • Research report: Adjuvant T-DM1 versus trastuzumab plus pertuzumab for residual disease after neoadjuvant dual HER2 blockade in HER2-positive early breast cancer: a multicenter real-world study

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Biotechnology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Editorial Policy
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Science News
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,151 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading